%0 Journal Article %1 Edick.2003 %A Edick, Mathew J. %A Gajjar, Amar %A Mahmoud, Hazem H. %A van de Poll, Matthijs E. C. %A Harrison, Patricia L. %A Panetta, John C. %A Rivera, Gaston K. %A Ribeiro, Raul C. %A Sandlund, John T. %A Boyett, James M. %A Pui, Ching-Hon %A Relling, Mary V. %D 2003 %J J Clin Oncol %K imported %N 7 %P 1340-1346 %T Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia %V 21 %X Purpose: To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL). Patients and Methods: Fifty-eight patients were randomly assigned to etoposide at 50 mg/m2/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy. Results: Of 48 patients with pharmacokinetic data, 42 (87.5%) achieved complete remission, three (6.3%) failed to achieve remission, and three (6.3%) died during induction. Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P = .06 and P = .07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micromol/L * h, respectively) than in patients (n = 3) who did not (14

@article{Edick.2003, abstract = {Purpose: To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL). Patients and Methods: Fifty-eight patients were randomly assigned to etoposide at 50 mg/m2/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy. Results: Of 48 patients with pharmacokinetic data, 42 (87.5%) achieved complete remission, three (6.3%) failed to achieve remission, and three (6.3%) died during induction. Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P = .06 and P = .07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 {micro}mol/L * h, respectively) than in patients (n = 3) who did not (14 }, added-at = {2010-02-04T16:31:48.000+0100}, author = {Edick, Mathew J. and Gajjar, Amar and Mahmoud, Hazem H. and van de Poll, Matthijs E. C. and Harrison, Patricia L. and Panetta, John C. and Rivera, Gaston K. and Ribeiro, Raul C. and Sandlund, John T. and Boyett, James M. and Pui, Ching-Hon and Relling, Mary V.}, biburl = {https://www.bibsonomy.org/bibtex/28aa5ebb3e255d5d8291bc0bbc7879003/hruehs}, interhash = {0b0ad5305d1018699bbcbd416d83d7ef}, intrahash = {8aa5ebb3e255d5d8291bc0bbc7879003}, journal = {J Clin Oncol}, keywords = {imported}, number = 7, pages = {1340-1346}, timestamp = {2010-02-04T16:31:51.000+0100}, title = {Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia}, volume = 21, year = 2003 }